Item 5.07 Submission of Matters to a Vote of Security Holders.
Ovid Therapeutics Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting") on June 10, 2026. As of April 15, 2026, the record date for the Annual Meeting, there were 173,037,131 shares of Company common stock outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 130,958,928 shares, or 75.7%, were present in person or represented by proxy, which constituted a quorum. Summarized below are descriptions of the proposals voted on at the Annual Meeting and the final results for each of the proposals. The proposals set forth below are described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 27, 2026 (the "Proxy Statement").
Proposal 1: The Company's stockholders elected the nominee for director to serve a three-year term until the Company's 2029 annual meeting of stockholders and until his successor has been duly elected and qualified, or, if sooner, until his death, resignation or removal, by the votes set forth in the table below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nominee
|
|
For
|
|
Withheld
|
|
Broker Non-Votes
|
|
Jeremy M. Levin, DPhil, MB BChir
|
|
87,219,707
|
|
8,528,008
|
|
35,211,213
|
Proposal 2: The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement, by the votes set forth in the table below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
|
84,511,953
|
|
|
8,901,691
|
|
2,334,071
|
|
35,211,213
|
Proposal 3: The Company's stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 by the votes set forth in the table below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
|
130,845,667
|
|
|
32,505
|
|
80,756
|
|
N/A
|